Credit: Miromatrix
Miromatrix, a UMN startup working to engineer organs for transplant, is being acquired by United Therapeutics Corporation for $91 million. This acquisition is part of United Therapeutics Corporation’s mission to rectify the shortage of transplantable organs. Miromatrix, which adds human cells to organs engineered from pig kidneys and livers to make them suitable for humans, was founded in 2009 based on research from the University of Minnesota and went public in 2021.
Miromatrix will be the 12th exit (either acquisition or initial public offering) for a UMN startup since 2017, a strong indicator of the value and impact of inventions coming out of the University.